Solvonis Therapeutics plc (LON:SVNS)

Market Cap	13.27M +30.2%
Revenue (ttm)	n/a
Net Income	-5.74M
EPS	-0.00
Shares Out	6.81B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,821,762
Open	0.1910
Previous Close	0.1950
Day's Range	0.1900 - 0.2050
52-Week Range	0.1710 - 0.4000
Beta	1.19
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 11, 2026

About Solvonis Therapeutics

Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops medicines for addiction, psychiatry, and neurology disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product consists of SVN-114 for the treatment of post-traumatic stress disorder; and SVN-015 for the treatment of stimulant use disorde...

• Industry: Specialty Industrial Machinery
• Sector: Industrials
• Founded: 2017
• Employees: 6
• Stock Exchange: London Stock Exchange
• Ticker Symbol: SVNS

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 24, 2026

Data Sources Report a data error